Cover Image
市場調查報告書

α1抗胰蛋白酶缺乏症:全球9個國家的市場預測

Alpha-1 Anti-Trypsin Deficiency Forecast in 9 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 371702
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
α1抗胰蛋白酶缺乏症:全球9個國家的市場預測 Alpha-1 Anti-Trypsin Deficiency Forecast in 9 Major Markets 2016-2026
出版日期: 2016年09月23日 內容資訊: 英文 36 Pages
簡介

本報告提供全球主要9個國家 (美國、法國、德國、義大利、西班牙、英國、巴西、日本、印度) 的α1抗胰蛋白酶缺乏症 (AATD) 治療的市場相關分析,各國的AATD的患病人數的變化和未來預測 (今後10年份),男女、各年齡層 (5歲分級) 及各重症度詳細趨勢,主要的併發症 (硬化,COPD (慢性阻塞性肺病),肺癌症,氣喘,脂膜炎,全身性血管炎等)的罹患情形,主要的風險要素,預後的差異 (各地區、各民族等),現在、未來的主要的治療方法,診斷、治療的實施情形等調查評估。

目錄

  • 簡介
  • 疾病的原因
  • 風險要素與預防法
  • 疾病診斷
  • 各地區、各民族的差異
  • 疾病的預後和臨床過程
  • 疾病相關的主要並存症/特徵
  • 患者數的定量化方法
  • α1抗胰蛋白酶缺乏症的患病人數的最大估計值 (top line)
  • α1抗胰蛋白酶缺乏症 (AATD)的患者數:各特徵
    • Pi表現型
    • AATD臨床症狀
  • 本文中的簡稱
  • 相關分析、資料庫
  • 註腳
  • 附錄

圖表一覽

目錄
Product Code: AATD0010916

Alpha-1 Anti-Trypsin (AAT) is an enzyme belonging to the serpin super family, and is also referred to as alpha-1 proteinase inhibitor (A1PI) because it inhibits a wide variety of proteases. AAT protects tissues from enzymes of inflammatory cells, especially neutrophil elastase protein. In its absence (such as in alpha 1-anti-trypsin deficiency), neutrophil elastase is free to break down elastin, which contributes to the elasticity of the lungs. This results in respiratory complications such as COPD (chronic obstructive pulmonary disease) in adults and cirrhosis of the liver in adults or children.

Alpha-1 Anti-Trypsin deficiency (AATD) is an inherited, rare condition that causes a complete or partial reduction in activity of Alpha-1 Anti-Trypsin (AAT) in the blood and lungs which leads to the deposit of excessive abnormal A1AT protein in liver cells.

This report provides the current prevalent population for Alpha-1 Anti-Trypsin across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Alpha-1 Anti-Trypsin have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Key underlying pathologies linked with developing Alpha-1 Anti-Trypsin include:

  • Cirrhosis
  • COPD
  • Lung Cancer
  • Asthma
  • Panniculitis
  • Systemic Vasculitis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in the global Alpha-1 Anti-Trypsin market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Alpha-1 Anti-Trypsin and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on the Alpha-1 Anti-Trypsin prevalent population.
  • Identify sub-populations within Alpha-1 Anti-Trypsin which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Alpha-1 Anti-Trypsin patients.

Coverage

  • BR
  • FR
  • DE
  • IN
  • IT
  • JP
  • ES
  • UK
  • US

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line prevalence for Alpha-1 Antitrypsin Deficiency
  • Features of AATD patients
    • Pi Phenotype
    • Clinical Manifestations of AATD
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • Prevalence of AATD, total (000s)
  • Prevalence of AATD, males (000s)
  • Prevalence of AATD, females (000s)
  • Protease inhibitor (Pi) phenotype of AATD patients, total (000s)
  • AATD patients with Cirrhosis, total (000s)
  • AATD patients with COPD, total (000s)
  • AATD patients with Lung Cancer, total (000s)
  • AATD patients with Asthma, total (000s)
  • AATD patients with Panniculitis, total (000s)
  • AATD patients with Systemic Vasculitis, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of AATD by 5-yr age cohort, males (000s)
  • USA Prevalence of AATD by 5-yr age cohort, females (000s)
  • France Prevalence of AATD by 5-yr age cohort, males (000s)
  • France Prevalence of AATD by 5-yr age cohort, females (000s)
  • Germany Prevalence of AATD by 5-yr age cohort, males (000s)
  • Germany Prevalence of AATD by 5-yr age cohort females (000s)
  • Italy Prevalence of AATD by 5-yr age cohort, males (000s)
  • Italy Prevalence of AATD by 5-yr age cohort, females (000s)
  • Spain Prevalence of AATD by 5-yr age cohort, males (000s)
  • Spain Prevalence of AATD by 5-yr age cohort, females (000s)
  • UK Prevalence of AATD by 5-yr age cohort, males (000s)
  • UK Prevalence of AATD by 5-yr age cohort, females (000s)
  • Brazil Prevalence of AATD by 5-yr age cohort, males (000s)
  • Brazil Prevalence of AATD by 5-yr age cohort, females (000s)
  • Japan Prevalence of AATD by 5-yr age cohort, males (000s)
  • Japan Prevalence of AATD by 5-yr age cohort, females (000s)
  • India Prevalence of AATD by 5-yr age cohort, males (000s)
  • India Prevalence of AATD by 5-yr age cohort, females (000s)
Back to Top